. Interface mutations that weaken the interaction between receptor and co-receptor in vitro reduce brassinosteroid signalling responses 2 . The SERK3 elongated (elg) allele 3-5 maps to the complex interface and shows enhanced brassinosteroid signalling, but surprisingly no tighter binding to the BRI1 ectodomain in vitro. Here, we report that rather than promoting the interaction with BRI1, the elg mutation disrupts the ability of the co-receptor to interact with the ectodomains of BRI1-ASSOCIATED-KINASE1 INTERACTING KINASE (BIR) receptor pseudokinases, negative regulators of LRR-RK signalling 6 . A conserved lateral surface patch in BIR LRR domains is required for targeting SERK co-receptors and the elg allele maps to the core of the complex interface in a 1.25 Å BIR3-SERK1 structure. Collectively, our structural, quantitative biochemical and genetic analyses suggest that brassinosteroid signalling complex formation is negatively regulated by BIR receptor ectodomains.
. The SERK3 elongated (elg) allele [3] [4] [5] maps to the complex interface and shows enhanced brassinosteroid signalling, but surprisingly no tighter binding to the BRI1 ectodomain in vitro. Here, we report that rather than promoting the interaction with BRI1, the elg mutation disrupts the ability of the co-receptor to interact with the ectodomains of BRI1-ASSOCIATED-KINASE1 INTERACTING KINASE (BIR) receptor pseudokinases, negative regulators of LRR-RK signalling 6 . A conserved lateral surface patch in BIR LRR domains is required for targeting SERK co-receptors and the elg allele maps to the core of the complex interface in a 1.25 Å BIR3-SERK1 structure. Collectively, our structural, quantitative biochemical and genetic analyses suggest that brassinosteroid signalling complex formation is negatively regulated by BIR receptor ectodomains.
The LRR-RK BRI1 is the major receptor for growth-promoting steroid hormones in plants 7, 8 and binds brassinosteroids including the potent brassinolide (BL) with its LRR ectodomain 9, 10 . Ligandassociated BRI1 can interact with the LRR domain of a SERK co-receptor kinase, which completes the steroid binding site 1, 11 . Heterodimerization of the receptor and co-receptor LRR domains at the cell surface enables the kinase domains of BRI1 and SERK to transphosphorylate each other, allowing BRI1 to activate the cytoplasmic side of the brassinosteroid signalling cascade [12] [13] [14] . Mutations in the BRI1-SERK complex interface that reduce binding between the receptor and co-receptor ectodomains in vitro, weaken the interactions of the full-length proteins in planta and consequently result in brassinosteroid loss-of-function phenotypes 2 . Previously, two gain-of-function mutations have been reported for the brassinosteroid signalling complex: the BRI1 sud1 allele stabilizes the steroid binding site of the receptor 1, 15 . A similar phenotype is observed with the elongated (elg) mutant 5 , originally identified as a suppressor of ga4, a gibberellic acid biosynthetic enzyme 3 . SERK3 D122 is replaced by an asparagine residue in elg mutant plants 4 and Asn122 maps to the constitutive BRI1-SERK3 complex interface outside the steroid binding pocket 1, 2, 11 (Fig. 1a) . In BRI1-SERK complex structures, SERK3
D122 stabilizes the conformation of SERK3
R146
, which in turn makes polar contacts with BRI1 E749 refs 1,2,9 ( Fig. 1a) . Mutation of the corresponding Asp128 to asparagine in rice SERK2 alters these interactions 16 . SERK3
D122 positions SERK3 E98 for interaction with BRI1 T750 , which is replaced by isoleucine in bri1-102 loss-offunction mutants 17 ( Fig. 1a) . Taken together, SERK3 D122 is in contact with several residues critically involved in brassinosteroid signalling complex formation.
We complemented a serk1-1 serk3-1 double mutant with 6xHA-tagged wild-type or SERK3 mutant genomic constructs under the control of the SERK3 promoter. We could recapitulate the gain-of-function phenotype of SERK3 D122N plants in quantitative hypocotyl growth assays 5 and replacing SERK3 D122 with alanine resulted in an even stronger brassinosteroid signalling phenotype (Fig. 1b,c (Fig. 1d) . SERK3 D122A but not SERK3 D122N has a slower dissociation rate (k d ) than the receptor, and consequently a slightly lower dissociation constant (K D ). Overall, the only moderately altered binding kinetics for wild-type versus mutant SERK3 ectodomains cannot rationalize their gain-of-function phenotype in planta (Fig. 1b-d) .
Recently, the BRI1-ASSOCIATED-KINASE1 INTERACTING KINASE 3 (BIR3) has been reported to be a negative regulator of brassinosteroid signalling in Arabidopsis 6 . Ectopic overexpression of BIR3 results in brassinosteroid loss-of-function phenotypes including BL insensitivity and reduced BRI1-EMS-SUPPRESSOR 1 (BES1) dephosphorylation 6 . The cytosolic pseudokinase domains of BIR2 and BIR3 bind the SERK3 kinase domain in yeast-2-hybrid assays and the full-length proteins interact in planta 6, 18 . We hypothesized that the highly conserved BIR ectodomains may contribute to BIR3-SERK3 complex formation. Indeed, we found that the recombinantly purified BIR3 LRR domain binds SERK3 with a K D of ~1 μ M and with 1:1 stoichiometry (N) in isothermal titration calorimetry (ITC) experiments (Fig. 2a) . No binding was detected between the BIR3 and BRI1 ectodomains (Fig. 2a) . The BIR3 and BIR2 ectodomains interact with SERK1-3 with similar binding affinities in vitro (K D ranges from ~1 to ~3 μ M) (Fig. 2a) . Binding affinities of SERK3 versus BIR1-4 ranging from ~1 to ~10 μ M have previously been reported 19 . The very similar biochemical properties of different BIR and SERK ectodomains allowed us to use different protein isoforms for our various biochemical and structural investigations described below. It is however of note that bir3 but not bir2-1 or bir2-3 mutant plants display a weak brassinosteroid gain-of-function signalling phenotype (Fig. 2c, Supplementary Figs . 2 and 5, and Supplementary Table 1) . SERK-BIR complex formation is likely to be driven by their extracellular LRR domains, as we could not observe detectable binding of the cytoplasmic (pseudo) kinase domains in ITC assays ( Supplementary Fig. 4 ).
We next tested whether the elg mutation could modulate the interaction between BIRs and SERK3. Indeed, the SERK3 and approximately eightfold reduced binding to BIR2 (Fig. 2a,b) . Owing to its low expression yield, the SERK3 D122A mutant (Fig. 1 ) could not be assayed by ITC. Together, our experiments suggest that SERK3 D122 maps to the interface of different SERK3-BIR complexes and that interactions between interface residues may be compromised in the elg mutant background.
To gain insight into the BIR targeting mechanism, we sought to determine a crystal structure of BIR3 but did not succeed in obtaining diffraction quality crystals. Crystals of the related BIR2 ectodomain (residues 29-221, ~60% sequence identity with BIR3) diffracted to 1.9 Å resolution (Supplementary Table 2 ). BIR2 contains five LRRs and shows a high degree of structural conservation with SERKs (root mean squared deviation (r.m.s.d) is ~1.5 Å comparing 175 corresponding C α atoms in BIR2 and SERK1) with the exception of a protruding loop in the amino (N)-terminal capping domain of BIR2 (magenta in Fig. 3a) . The BIR2 N-and carboxy Letters Nature PlaNts (C)-terminal caps as well as the LRR core are stabilized by disulfide bridges conserved among the different BIR family members ( Fig. 3c and Supplementary Fig. 6 ). The conserved Asn58 in the BIR2 N-cap is glycosylated in our structure ( Fig. 3c and Supplementary Fig. 6 ). A set of solvent-exposed hydrophobic residues including BIR2 W73 from the protruding loop, BIR2
F128
, BIR2 F152 and BIR2 R176 form a lateral surface patch conserved among BIRs from different species, but not in SERK proteins (Fig. 3b,c and Supplementary Fig. 6 ). This potential interaction surface differs from the central binding platform used by SERKs for targeting ligand-sensing LRR-RKs ( Fig. 3c ) 2, 14 . We generated several point mutations in the respective surface areas and assayed the mutant proteins versus SERK3 in ITC assays. BIR2 E84R and BIR2 V157D originating from the central LRR groove still bind SERK3, suggesting that this interaction platform is not used by BIRs to target SERKs (Fig. 3c,d ). Mutation of BIR2 W73 from the protruding N-cap loop to alanine weakens the interaction with SERK3 and replacing BIR2 F152 or BIR2 R176 from the lateral surface patch with alanine disrupts binding (Fig. 3c,d ). Thus, the unique N-cap loop and the lateral surface patch in the LRR domain of BIR2 are involved in the interaction with SERK3.
To understand how BIRs target the central, elg-containing surface in SERKs, we performed crystallization trials for various BIR-SERK ectodomain combinations. We obtained crystals for BIR3-SERK1 and BIR3-SERK2 complexes diffracting to 1.25 Å and 2.2 Å resolution, respectively (Supplementary Table 2 ). Our crystals contain a fully glycosylated BIR3-SERK1 heterodimer in the asymmetric unit, consistent with the in solution behaviour of the complex ( Fig. 4a and Supplementary Fig. 7 ). Most surface areas of the SERK1 LRR domain are shielded by carbohydrate, except for the central interaction surface used to, for example, bind the BRI1 and HAESA ligand-sensing LRR-RKs 1, 29, 20 . Structural superposition of our BIR3-SERK1 and BIR3-SERK2 complexes reveals that BIRs have a conserved SERK binding mode ( Supplementary Fig. 8A , r.m.s.d. is ~1.8 Å comparing 316 corresponding C α atoms), rationalizing their similar complex dissociation constants (Fig. 2a,b) . Comparing the BIR3-SERK1 complex with structures of the isolated SERK1 and BIR2 ectodomains reveals no major conformational rearrangements in BIRs and SERKs on complex formation, with the exception of the protruding loop containing BIR2 W73 or the corresponding Trp67 in BIR3 ( Supplementary Fig. 8b ). In the complex structure, BIR3 establishes a network of hydrophobic and polar interactions with the SERK1 C-terminal cap and with the two C-terminal LRRs (the total buried complex surface area is ~1,400 Å 2 as calculated with the program DSSP 21 ) (Fig. 4a) . Several polar contacts are mediated by water molecules. The tip of the BIR3 protruding N-cap loop is in direct contact with the SERK1 elg surface (Fig. 4b) . SERK residues Asp122 (numbering corresponds to SERK3 throughout) and the neighbouring Tyr124 together coordinate a water molecule, which in turn hydrogen bonds with BIR3 E69 in the protruding loop tip (Fig. 4b) . The neighbouring Tyr100 establishes an additional hydrogen bond with BIR3 E69 and the remaining loop tip residues BIR3 N68 and BIR3 K70 form similar interaction with SERK residues Asn148 and Asn77, respectively (Fig. 4b) . Importantly, mutation of SERK Tyr100 or Tyr124 to alanine reduces BIR2 binding (Fig. 4b,d ).
An additional set of hydrophobic contacts involving BIR3 W67 (corresponds to BIR2 W73 analysed in Fig. 3c,d , see Fig. 3c,d ) and SERK residues Val168, Ile192, Pro191 dominates the interactions between the BIR3 and SERK1 C-terminal halves (Fig. 4a,c) . BIR3 R170 , the corresponding mutation in BIR2 R176 to alanine disrupts complex formation with SERK3 (Fig. 3d) , forms hydrogen bonds with backbone atoms in the SERK1 C-cap and other polar contacts are mediated by water molecules (Fig. 4c) . Taken together, BIR3 targets the central LRR surface of SERKs normally used for the interaction with ligand-sensing LRR-RKs. The unique protruding loop in BIRs 
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Nature PlaNts directly contacts the elg surface patch, rationalizing the reduced binding of SERK3 D122N to BIR ectodomains in vitro (Fig. 2a,b) . We next tested if the SERK-BIR LRR domain complex interface controls association of the full-length proteins in planta. We found that wild-type SERK3 is associated with BIR3 in co-immunoprecipitation experiments (Fig. 4f) , as shown previously 6 . The  SERK3   D122N   , SERK3   D122A   , SERK3   Y100A   , SERK3 Y124A mutants, all of which show reduced binding to isolated BIR LRR domains in vitro, consistently show reduced interaction with BIR3 in vivo (Fig. 4f) . SERK3 F60 lies outside the SERK-BIR complex interface, but forms part of the BRI1-SERK steroid binding pocket 1, 11 and its mutation to alanine disrupts brassinosteroid complex formation in vitro and in planta 2 . Consistent with our BIR targeting model, the SERK3 F60A mutant shows wild-type binding to BIRs in ITC assays and retains interaction with BIR3 in vivo (Fig. 4d,f) .
Our biochemical observation that SERKs can form tight heterodimeric complexes with BRI1 or with BIRs using largely overlapping interaction surfaces (Supplementary Fig. 9 ) prompted us to investigate if the BRI1 and BIR ectodomains could compete for SERK binding. We performed analytical size-exclusion chromatography experiments with the isolated BRI1, SERK3 and BIR2 LRR domains and in the presence or absence of the steroid hormone. In our ITC assay (Fig. 2a) , we could not detect complex formation between BRI1 and BIR3, and consistently BIR2 was unable to dissociate an already formed BRI1-BL-SERK3 complex (Fig. 4g) . However, BRI1-BL could efficiently compete with BIR2 for SERK3 binding (Fig. 4g ), in line with our observation that the experimentally determined stoichiometries, binding affinities and binding kinetics for the different complexes are similar (Figs. 1d and 2a) .
Taken together, the molecular characterization of the SERK3 elg allele has revealed that the brassinosteroid signalling pathway is under negative regulation by the ectodomain of BIR3. We show that SERK3 D122N disrupts BIR but not BRI1 binding and thus exhibits a gain-of-function phenotype (Figs. 1c and 2b) . Mutation of the neighbouring SERK3 Y100 and SERK3 Y124 to alanine strongly decreases BIR binding, but only SERK3
Y124A retains the ability to bind BRI1-BL with high affinity (Fig. 4d-f) . Consistently, SERK3
Y124A , but not SERK3 Y100A or SERK3 Y100A/Y124A displays a 
Nature PlaNts statistically significant gain-of-function phenotype in hypocotyl growth assays (Fig. 1b,c) . The brassinosteroid-specific nature of the elg allele may thus be related to its ability to bind BRI1, but not other SERK3-dependent LRR-RKs with high affinity 5 . Indeed, we find that SERK3 D122N and SERK3 D122A mutant proteins bind the SERK-dependent peptide hormone receptor kinase HAESA with drastically reduced affinity (Supplementary Fig. 10 ). The elg and bir3 phenotypes and our quantitative biochemical assays reveal that BRI1 and BIRs can compete for binding to SERKs, with BRI1 being able to out-compete BIRs in the presence of BL. We speculate that this negative regulation of SERKs by BIR proteins may allow for sharper signal transitions, with signalling competent brassinosteroid complexes forming only in response to significant changes in brassinosteroid concentration.
Specific physiological functions have been genetically assigned to the different BIR family members in Arabidopsis: BIR1, a catalytically active protein kinase, specifically inhibits SERK3 co-receptor function in immunity and cell death, with bir1 loss-of-function mutants showing constitutive defence responses associated with a severe growth phenotype 19, 22, 23 . BIR2 and BIR3 are additional SERK3 interactors and both proteins are pseudokinases 6, 18, 24 . Different bir2 knockdown lines show altered immune responses but no brassinosteroid signalling phenotype, whereas bir3 loss-and gain-of function mutants affect brassinosteroid signalling (Fig. 2c ) 6, 18 . We cannot rationalize these specific functions of the different BIRs at the biochemical level, as all BIR ectodomains tested bind various SERK proteins with similar dissociation constants (Fig. 2a) , in agreement with a recent study on the role of BIR1 in FLS2-mediated immune signalling 19 . This behaviour of BIR proteins is reminiscent of SERKs, which also are largely promiscuous at the biochemical level, but which show partly specific, partly overlapping functions in plant growth, development and immunity 14 . BIR ectodomains and not their cytosolic kinase domains allow high affinity SERK binding (Figs. 2-4 and Supplementary Fig. 4 ), but BIR signalling specificity may be encoded in their cytosolic domains, as seen with ligandsensing LRR-RKs 2, 25 . In line with this, specific BIR adapter proteins have been reported 26, 27 , which could allow for the targeting of BIR family members to specific membrane (nano)-domains 28 , and which could help to create specific signalling outputs in the cytosol 26 . We cannot rule out a redundant function for BIR receptor kinases, but the fact that the bir3-2 mutant does not phenocopy elg plants (Figs. 1b and 2c) suggests that other negative regulators of brassinosteroid signalling complexes remain to be discovered.
Methods
See the Supplementary Information for complete details.
Reproducibility. At least two independent experiments were performed for all biochemical assays (ITC, GCI and gel filtration assays). Co-IP, hypocotyl growth assays and western blots were performed at least three times, all with similar outcome.
Protein expression and purification of LRR ectodomains. SERK2 , SERK3 and BRI1 were amplified from A. thaliana cDNA and BIR1 , BIR2
1-222 , BIR3
1-213 from A. thaliana genomic DNA. In addition, BIR2 1-222 was obtained codon optimized for expression in Trichoplusia ni (strain Tnao38); SERK1 and HAESA were obtained codon optimized and fused to an azurocidin signal peptide; all constructs were cloned in a modified pFastBac vector (Geneva Biotech) containing a TEV (tobacco etch virus protease) cleavable C-terminal StrepII-9xHis tag. Mutations were created using site-directed mutagenesis (Supplementary Table 3 ). Grating-coupled interferometry. The Creoptix WAVE system (Creoptix AG, Switzerland), a label-free surface biosensor 30 was used to perform GCI experiments. All experiments were performed on 2PCP WAVEchips (quasiplanar polycarboxylate surface; Creoptix AG, Switzerland). After a borate buffer conditioning (100 mM sodium borate pH 9.0, 1 M NaCl; Xantec, Germany) the respective LRR ectodomain was immobilized on the chip surface using standard amine-coupling: 7 min activation (1:1 mix of 400 mM N-(3-dimethylaminopropyl)-N′ -ethylcarbodiimide hydrochloride and 100 mM N-hydroxysuccinimide (both Xantec, Germany)), injection of the LRR domain (10-40 μ g ml −1 ) in 10 mM sodium acetate pH 5.0 (Sigma, Germany) until the desired density was reached, passivation of the surface (0.5% BSA (Roche, Switzerland) in 10 mM sodium acetate pH 5.0) and final quenching with 1 M ethanolamine pH 8.0 for 7 min (Xantec, Germany). For a typical experiment, SERK3 was injected in a 1:2 dilution series (starting from 2 μ M) in 20 mM citrate pH 5.0, 250 mM NaCl at 25 °C. Blank injections were used for double referencing and a dimethylsulfoxide (DMSO) calibration curve for bulk correction. Analysis and correction of the obtained data was performed using the Creoptix WAVEcontrol software (applied corrections, X and Y offset; DMSO calibration; double referencing) and a one-to-one binding model with bulk correction was used to fit all experiments.
Isothermal titration calorimetry. All ITC experiments were performed on a Nano ITC (TA Instruments) with a 1.0 ml standard cell and a 250 μ l titration syringe at 25 °C. Proteins were gelfiltrated or dialysed into ITC buffer (20 mM sodium citrate pH 5.0, 150 mM NaCl for LRR domains; 20 mM Hepes pH 7.5, 150 mM NaCl, 1 mM MgCl 2 , 0.5 mM tris(2-carboxyethyl)phosphine (TCEP) for kinase domains) prior to all experiments. For a typical ectodomain experiment, 16 μ l of BIR (at ~400 μ M) was injected into ~40 μ M SERK protein in the cell at 150 s intervals (15 injections) . Experiments with the kinase domains were performed by injecting 10 μ l of BIR2 or BRI1 cytosolic domain at ~200 μ M into ~20 μ M of SERK3 kinase domain in the cell at 150 s intervals (25 injections). Data was corrected for the dilution heat and analysed using NanoAnalyze program (version 3.5) as provided by the manufacturer.
Plant protein extraction and immunoprecipitation. Surface-sterilized and stratified seeds were plated on ½ MS, 0.8 % agar plates and grown for ~14 days. Seedlings were frozen in liquid nitrogen, ground to fine powder using mortar and pestel (1 g per sample) and resuspended in 3 ml of ice cold extraction buffer (50 mM Bis Tris pH 7.0, 150 mM NaCl, 10 % (v/v) glycerol, 1% Triton X-100, 5 mM dithiothreitol, protease inhibitor cocktail (P9599, Sigma). After gentle agitation for 1 h at 4 °C, samples were centrifuged for 30 min at 4 °C and 16,000g; the supernatant was transferred to a fresh tube and the protein concentration measured using a Bradford assay. A 20 mg bolus of total protein in a volume of 5 ml were incubated with 50 μ l of anti-HA superparamagnetic MicroBeads (Miltenyi Biotec) for 1 h at 4 °C with agitation for each co-immunoprecipitation (Co-IP). The beads were then collected using μ MACS Columns (Miltenyi Biotec), washed 4 times with 1 ml of cold extraction buffer and proteins were eluted in 20 + 20 μ l of extraction buffer at 95 °C. Samples were separated on 10% SDS-PAGE gels. In the subsequent western blots SERK3:6HA was detected using anti-HA antibody coupled to horse radish peroxidase (HRP, Miltenyi Biotec) at 1:5,000 dilution, while BIR3 was detected using a polyclonal BIR3 antibody 6 at 1:500 dilution followed a secondary anti-rabbit HRP antibody (1:10,000, Calbiochem #401353). Co-immunoprecipitation experiments were repeated two times, with similar outcome.
Analytical size-exclusion chromatography. Gel filtration experiments were performed using a Superdex 200 Increase 10/300 GL column (GE Healthcare) preequilibrated in either 20 mM sodium citrate pH 5.0, 150 mM NaCl for LRR domain interaction assays, or with 20 mM Hepes pH 7.5, 150 mM NaCl, 1 mM MgCl 2 , 0.5 mM TCEP for cytoplasmic domain oligomeric state analysis. A 500 μ l bolus of the respective protein (0.2 mg ml ) was loaded sequentially onto the column and elution at 0.75 ml min −1 was monitored by ultraviolet absorbance at 280 nm. The BL concentration was 1 μ M in the BRI1-BL-SERK3 complex sample prior to loading.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. Materials used in this study and data generated are available from the corresponding author upon request. Crystallographic coordinates and structure factors have been deposited with the Protein Data Bank (http://rcsb.org) with accession codes 6FG7 (BIR2), 6FG8 (BIR3-SERK1) and 6G3W (BIR3-SERK2).
nature research | life sciences reporting summary

November 2017
Corresponding author(s): Michael Hothorn Life Sciences Reporting Summary Nature Research wishes to improve the reproducibility of the work that we publish. This form is intended for publication with all accepted life science papers and provides structure for consistency and transparency in reporting. Every life science submission will use this form; some list items might not apply to an individual manuscript, but all fields must be completed for clarity.
For further information on the points included in this form, see Reporting Life Sciences Research. For further information on Nature Research policies, including our data availability policy, see Authors & Referees and the Editorial Policy Checklist.
Please do not complete any field with "not applicable" or n/a. Refer to the help text for what text to use if an item is not relevant to your study. For final submission: please carefully check your responses for accuracy; you will not be able to make changes later.
Experimental design 1 . Sample size Describe how sample size was determined.
No statistical methods were employed to predetermine sample size. For the hypocotyl growth assay, the sample size was chosen as large as possible under the given technical restrictions.
Data exclusions
Describe any data exclusions.
No data were excluded for all in vivo and in vitro experiments. 5% of the crystallographic structure amplitudes were excluded for cross-validation, as it is standard in the field.
Replication
Describe the measures taken to verify the reproducibility of the experimental findings.
All attempts at replication were successful. Biochemical experiments (ITC, GCI and gelfiltration assays) were repeated independently at least twice, Co-IP, hypocotyl growth assays and western blots at least three times
Randomization
Describe how samples/organisms/participants were allocated into experimental groups.
wild-type and mutant SERK3 alleles were randomized for the quantitative hypocotyl growth assay (seedlings on plates).
Blinding
Describe whether the investigators were blinded to group allocation during data collection and/or analysis.
Genotypes were not known a priori when measuring hypocotyl length via tracking with Fiji. Note: all in vivo studies must report how sample size was determined and whether blinding and randomization were used.
Statistical parameters
For all figures and tables that use statistical methods, confirm that the following items are present in relevant figure legends (or in the Methods section if additional space is needed).
n/a Confirmed
The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement (animals, litters, cultures, etc.)
A description of how samples were collected, noting whether measurements were taken from distinct samples or whether the same sample was measured repeatedly A statement indicating how many times each experiment was replicated
The statistical test(s) used and whether they are one-or two-sided A clear description of statistics including central tendency (e.g. median, mean) and variation (e.g. standard deviation, interquartile range)
Clearly defined error bars in all relevant figure captions (with explicit mention of central tendency and variation)
See the web collection on statistics for biologists for further resources and guidance.
